Literature DB >> 18838451

Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection.

Sandra Dial1, Abbas Kezouh, Andre Dascal, Alan Barkun, Samy Suissa.   

Abstract

BACKGROUND: Previous observations have indicated that infection with Clostridium difficile occurs almost exclusively after exposure to antibiotics, but more recent observations have suggested that prior antibiotic exposure may be less frequent among cases of community-acquired disease.
METHODS: We used 2 linked health databases to perform a matched, nested case-control study of elderly patients admitted to hospital with community-acquired C. difficile infection. For each of 836 cases among people 65 years of age or older, we selected 10 controls. We determined the proportion of cases that occurred without prior antibiotic exposure and estimated the risk related to exposure to different antibiotics and the duration of increased risk.
RESULTS: Of the 836 cases, 442 (52.9%) had no exposure to antibiotics in the 45-day period before the index date, and 382 (45.7%) had no exposure in the 90-day period before the index date. Antibiotic exposure was associated with a rate ratio (RR) of 10.6 (95% confidence interval [CI] 8.9-12.8). Clindamycin (RR 31.8, 95% CI 17.6-57.6), cephalosporins (RR 14.9, 95% CI 10.9-20.3) and gatifloxacin (RR 16.7, 95% CI 8.3-33.6) were associated with the highest risk. The RR for C. difficile infection associated with antibiotic exposure declined from 15.4 (95% CI 12.2-19.3) by about 20 days after exposure to 3.2 (95% CI 2.0-5.0) after 45 days. Use of a proton pump inhibitor was associated with increased risk (RR 1.6, 95% CI 1.3-2.0), as were concurrent diagnoses of inflammatory bowel disease (RR 4.1, 95% CI 2.6-6.6), irritable bowel syndrome (RR 3.4, 95% CI 2.3-5.0) and renal failure (RR 1.7, 95% CI 1.2-2.2).
INTERPRETATION: Community-acquired C. difficile infection occurred in a substantial proportion of individuals with no recent exposure to antibiotics. Among patients who had been exposed to antibiotics, the risk declined markedly by 45 days after discontinuation of use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18838451      PMCID: PMC2553880          DOI: 10.1503/cmaj.071812

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  24 in total

Review 1.  Narrative review: the new epidemic of Clostridium difficile-associated enteric disease.

Authors:  John G Bartlett
Journal:  Ann Intern Med       Date:  2006-11-21       Impact factor: 25.391

2.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

Authors:  Vivian G Loo; Louise Poirier; Mark A Miller; Matthew Oughton; Michael D Libman; Sophie Michaud; Anne-Marie Bourgault; Tuyen Nguyen; Charles Frenette; Mirabelle Kelly; Anne Vibien; Paul Brassard; Susan Fenn; Ken Dewar; Thomas J Hudson; Ruth Horn; Pierre René; Yury Monczak; André Dascal
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

3.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

4.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

5.  Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study.

Authors:  Donna O Lowe; Muhammad M Mamdani; Alexander Kopp; Donald E Low; David N Juurlink
Journal:  Clin Infect Dis       Date:  2006-10-13       Impact factor: 9.079

6.  Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy.

Authors:  Sandra Dial; J A Chris Delaney; Verena Schneider; Samy Suissa
Journal:  CMAJ       Date:  2006-09-26       Impact factor: 8.262

7.  Accuracy of ICD-9 coding for Clostridium difficile infections: a retrospective cohort.

Authors:  D B Scheurer; L S Hicks; E F Cook; J L Schnipper
Journal:  Epidemiol Infect       Date:  2006-12-07       Impact factor: 2.451

Review 8.  The challenges posed by reemerging Clostridium difficile infection.

Authors:  David B Blossom; L Clifford McDonald
Journal:  Clin Infect Dis       Date:  2007-06-04       Impact factor: 9.079

9.  Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost.

Authors:  M W Climo; D S Israel; E S Wong; D Williams; P Coudron; S M Markowitz
Journal:  Ann Intern Med       Date:  1998-06-15       Impact factor: 25.391

10.  ICD-9 codes and surveillance for Clostridium difficile-associated disease.

Authors:  Erik R Dubberke; Kimberly A Reske; L Clifford McDonald; Victoria J Fraser
Journal:  Emerg Infect Dis       Date:  2006-10       Impact factor: 6.883

View more
  53 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

2.  Use administrative databases with caution.

Authors:  Bruno Hubert; Rodica Gilca
Journal:  CMAJ       Date:  2009-01-06       Impact factor: 8.262

3.  Are there reasons to prefer tetracyclines to macrolides in older patients with community-acquired pneumonia?

Authors:  S Di Bella; F Taglietti; N Petrosillo
Journal:  Antimicrob Agents Chemother       Date:  2013-08       Impact factor: 5.191

4.  Probiotics for the prevention of Clostridium difficile.

Authors:  Daniel Rainkie; Michael R Kolber
Journal:  Can Fam Physician       Date:  2013-09       Impact factor: 3.275

5.  Clostridium difficile infection in the community: are proton pump inhibitors to blame?

Authors:  Daniel E Freedberg; Julian A Abrams
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

Review 6.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

7.  Spectrum of Clostridium difficile infections outside health care facilities.

Authors:  Ed J Kuijper; Jaap T van Dissel
Journal:  CMAJ       Date:  2008-10-07       Impact factor: 8.262

8.  Epidemiology and outcomes of community-acquired Clostridium difficile infections in Medicare beneficiaries.

Authors:  Courtney E Collins; M Didem Ayturk; Julie M Flahive; Timothy A Emhoff; Frederick A Anderson; Heena P Santry
Journal:  J Am Coll Surg       Date:  2014-02-28       Impact factor: 6.113

9.  Synthesis and evaluation of oryzalin analogs against Toxoplasma gondii.

Authors:  Molla M Endeshaw; Catherine Li; Jessica de Leon; Ni Yao; Kirk Latibeaudiere; Kokku Premalatha; Naomi Morrissette; Karl A Werbovetz
Journal:  Bioorg Med Chem Lett       Date:  2010-07-08       Impact factor: 2.823

10.  Clostridium difficile as a cause of acute diarrhea: a prospective study in a tertiary care center.

Authors:  Meghraj Ingle; Abhijit Deshmukh; Devendra Desai; Philip Abraham; Anand Joshi; Tarun Gupta; Camilla Rodrigues
Journal:  Indian J Gastroenterol       Date:  2013-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.